Although our data point towards a functional role of MHC-II expression as contributing to sensitivity to PD-1/PD-L1 axis inhibition, it is important to note that some tumours responded to PD-1-targeted therapy, despite having no detectable MHC-II expression. The gene discussed is CD274; the disease is neoplasm.